Carboplatin AUC, French Formula

Obese correction not included

Loading...

Obese correction not included

yo
mg/mL*min

References

  1. Jennifer S Lees. Accuracy of glomerular filtration rate estimates among patients with cancer.. British journal of cancer, 2025
  2. Bram C Agema. From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology.. Drugs, 2025
  3. NA. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.. Kidney international, 2024
  4. A. Horiike. Adjustment of creatinine (Cr) to avoid severe thrombocytopenia of carboplatin (C) plus gemcitabine (G) in non-small cell lung cancer (NSCLC).. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016
  5. M. Okera. The effect of Cockcroft-Gault (CG) measurement of GFR on carboplatin dosage in ovarian cancer patients compared with Cr51-EDTA.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011
  6. Antonin Schmitt. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010
  7. M. Etienne. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.. Annals of oncology : official journal of the European Society for Medical Oncology, 2003
  8. E. Chatelut. Prediction of carboplatin clearance from standard morphological and biological patient characteristics.. Journal of the National Cancer Institute, 1995
  9. D. Jodrell. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992
  10. A H Calvert. Carboplatin dosage: prospective evaluation of a simple formula based on renal function.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989